A Prospective Multi-centre, Non-randomized, Open-label, Non-interventional Study to Evaluate the Safety, Efficacy and Injection Compliance of Scilin N, Scilin R or Scilin M30 in Chinese Type 2 Diabetes Mellitus (T2DM)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms SEAS
- 13 Jan 2015 Biomarkers information updated
- 04 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 14 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.